Moderna Inc (MRNA)
54.63
+0.27
(+0.50%)
USD |
NASDAQ |
Nov 01, 16:00
55.00
+0.37
(+0.68%)
After-Hours: 20:00
Moderna Enterprise Value: 12.51B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 12.51B |
| October 31, 2024 | 12.41B |
| October 30, 2024 | 12.55B |
| October 29, 2024 | 12.74B |
| October 28, 2024 | 12.58B |
| October 25, 2024 | 11.92B |
| October 24, 2024 | 11.81B |
| October 23, 2024 | 12.03B |
| October 22, 2024 | 12.04B |
| October 21, 2024 | 12.19B |
| October 18, 2024 | 12.31B |
| October 17, 2024 | 12.58B |
| October 16, 2024 | 13.60B |
| October 15, 2024 | 13.54B |
| October 14, 2024 | 13.70B |
| October 11, 2024 | 13.92B |
| October 10, 2024 | 13.36B |
| October 09, 2024 | 14.14B |
| October 08, 2024 | 13.96B |
| October 07, 2024 | 14.08B |
| October 04, 2024 | 14.65B |
| October 03, 2024 | 14.99B |
| October 02, 2024 | 15.79B |
| October 01, 2024 | 16.09B |
| September 30, 2024 | 17.20B |
| Date | Value |
|---|---|
| September 27, 2024 | 16.79B |
| September 26, 2024 | 16.09B |
| September 25, 2024 | 15.97B |
| September 24, 2024 | 16.09B |
| September 23, 2024 | 16.17B |
| September 20, 2024 | 16.76B |
| September 19, 2024 | 17.66B |
| September 18, 2024 | 18.37B |
| September 17, 2024 | 19.18B |
| September 16, 2024 | 18.10B |
| September 13, 2024 | 17.76B |
| September 12, 2024 | 18.30B |
| September 11, 2024 | 22.08B |
| September 10, 2024 | 21.99B |
| September 09, 2024 | 20.96B |
| September 06, 2024 | 19.53B |
| September 05, 2024 | 19.74B |
| September 04, 2024 | 19.38B |
| September 03, 2024 | 19.55B |
| August 30, 2024 | 21.26B |
| August 29, 2024 | 21.34B |
| August 28, 2024 | 21.63B |
| August 27, 2024 | 21.87B |
| August 26, 2024 | 22.90B |
| August 23, 2024 | 23.20B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
4.317B
Minimum
Nov 06 2019
187.56B
Maximum
Aug 09 2021
46.29B
Average
40.27B
Median
Oct 05 2022
Enterprise Value Benchmarks
| Eli Lilly and Co | 805.11B |
| Merck & Co Inc | 284.75B |
| Pfizer Inc | 221.03B |
| Novavax Inc | 616.13M |
| Amgen Inc | 222.98B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.279B |
| Revenue (Quarterly) | 221.00M |
| Total Expenses (Quarterly) | 1.584B |
| EPS Diluted (Quarterly) | -3.33 |
| Gross Profit Margin (Quarterly) | 47.96% |
| Profit Margin (Quarterly) | -578.7% |
| Earnings Yield | -28.15% |
| Normalized Earnings Yield | -27.76 |